JP Morgan Chase’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VKTX
JP Morgan Chase's VKTX Position: Q2 2026 in Review
JP Morgan Chase increased its Viking Therapeutics (VKTX) stake by 88% in Q2 2026, buying an estimated $13.9M and bringing the position to 915,185 shares worth $36.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1709.
JP Morgan Chase first reported a position in VKTX in Q2 2018 and has held it in 33 quarters since. The position peaked at $134M in Q3 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.
- JP Morgan Chase held 915,185 shares of Viking Therapeutics worth $36.4M as of Q2 2026.
- JP Morgan Chase bought 429,482 Viking Therapeutics shares in Q2 2026, an estimated $13.9M.
- Viking Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #1709 holding.
- JP Morgan Chase first reported a position in Viking Therapeutics in Q2 2018 and has held it in 33 quarters since.
- JP Morgan Chase's Viking Therapeutics position peaked at $134M in Q3 2024.
- 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.